Cremonini F, Talley N J
Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER) Program, Mayo Clinic, Rochester, MN, USA.
Aliment Pharmacol Ther. 2004 Nov;20 Suppl 7:40-9. doi: 10.1111/j.1365-2036.2004.02184.x.
Functional dyspepsia and irritable bowel syndrome are currently considered to be two separate nosological entities. However, the overlap of symptoms and the evidence of a number of common pathophysiological characteristics suggest that functional dyspepsia and irritable bowel syndrome may be different presentations of the same disorder. In this review, we critically appraise points in common, as well as differences, in the epidemiology, pathophysiology and response to treatment of functional dyspepsia and irritable bowel syndrome. Population-based studies and large case series show that one- to two-thirds of subjects with irritable bowel syndrome have symptoms that overlap with functional dyspepsia. Symptom analyses have generally failed to support functional dyspepsia and irritable bowel syndrome as separate entities. An exaggerated motor response to meals, delayed gastric emptying and abnormal small bowel and colonic transit can all be found in subsets of functional dyspepsia and irritable bowel syndrome, and are not exclusive to either condition. Visceral hypersensitivity is a common feature to both entities and seems unlikely to be site or disease specific. There is good evidence for the post-infectious development of irritable bowel syndrome, and this may also apply in functional dyspepsia. Psychiatric comorbidities are similar in functional dyspepsia and irritable bowel syndrome. Several common drug classes (prokinetics, visceral analgesics, psychoactive agents) may similarly improve both functional dyspepsia and irritable bowel syndrome symptoms. The evidence available suggests that at least subsets of functional dyspepsia and irritable bowel syndrome represent different manifestations of a single entity. The identification of common pathophysiological targets for therapy should be pursued in future research.
功能性消化不良和肠易激综合征目前被认为是两种不同的疾病实体。然而,症状的重叠以及一些共同病理生理特征的证据表明,功能性消化不良和肠易激综合征可能是同一疾病的不同表现形式。在本综述中,我们批判性地评估了功能性消化不良和肠易激综合征在流行病学、病理生理学及对治疗反应方面的共同点和差异。基于人群的研究和大型病例系列表明,三分之一至三分之二的肠易激综合征患者有与功能性消化不良重叠的症状。症状分析总体上未能支持将功能性消化不良和肠易激综合征视为不同的实体。对进餐的运动反应过度、胃排空延迟以及小肠和结肠转运异常在功能性消化不良和肠易激综合征的部分患者中均可见,并非某一种疾病所特有。内脏高敏感性是这两种疾病的共同特征,似乎并非特定于某个部位或某种疾病。有充分证据表明肠易激综合征可在感染后发生,这可能也适用于功能性消化不良。功能性消化不良和肠易激综合征的精神共病情况相似。几类常用药物(促动力药、内脏镇痛药、精神活性药物)可能同样能改善功能性消化不良和肠易激综合征的症状。现有证据表明,至少功能性消化不良和肠易激综合征的部分患者代表了单一实体的不同表现形式。未来研究应致力于确定共同的病理生理治疗靶点。
Aliment Pharmacol Ther. 2004-11
Eur J Gastroenterol Hepatol. 2006-10
Rev Gastroenterol Disord. 2001
BMC Gastroenterol. 2008-9-23
Am J Gastroenterol. 1997-6
Schweiz Med Wochenschr. 2000-11-18
Minerva Gastroenterol Dietol. 2005-9
Rev Gastroenterol Disord. 2006
Healthcare (Basel). 2024-11-21
BMC Med Inform Decis Mak. 2023-8-26
Cureus. 2021-1-14
World J Gastroenterol. 2017-10-7
Korean J Intern Med. 2014-3
Int J Colorectal Dis. 2012-5-10